Medtronic platform acquired
September 2, 2024
Source: drugdu
98
Recently, PaceMate, a provider of cardiac remote monitoring solutions, announced that it has successfully acquired Medtronic's localized cardiac workflow solution Paceart Optima. However, the financial details of the transaction have not yet been disclosed to the public.
As an innovator of cardiac health data management solutions, PaceMate has gained wide recognition in recent years for its remote monitoring technology. The integration of the Paceart Optima system is expected to add nearly 1,000 new clinic partners worldwide.
For Medtronic, this divestiture is in line with its overall strategy of focusing resources on core innovation and therapeutic advances. PaceMate has further consolidated its market leadership and expanded its global influence by increasing the depth and breadth of its services. Next, Medtronic's cardiac rhythm management (CRM) business will work closely with PaceMate to ensure a smooth transition.
https://mp.weixin.qq.com/s/GQmozVWWkMxQcAebSM4T-Q
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions November 22, 2024
- Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan November 22, 2024
- Junshi Biotechnology introduces two cancer dual target fusion protein drugs November 22, 2024
- China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical November 22, 2024
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
